Activity Description & Educational Objectives
In this activity, experts in rheumatology discuss the impact, pathophysiology, clinical presentation, and diagnosis of RA, as well as the principles of tight control and treating disease to target.
Upon completion of this activity, participants should be better able to:
- Discuss comorbidities, risk factors, and quality of life issues associated with rheumatoid arthritis (RA)
- Describe the pathophysiology of RA in the context of clinical presentation and therapeutic targets
- Apply updated classification criteria for RA to facilitate early diagnosis of disease
- Recognize the impact of early treatment and tight control on long-term patient outcomes in RA
- Discuss the value of individualizing therapy based on patient factors and treat-to-target goals
This activity has been designed to meet the educational needs of rheumatologists, rheumatology nurses, and other clinicians involved in the management of patients with RA.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Release and Expiration Dates: June 12, 2012 - June 11, 2013
Time to Complete: 30 minutes
Faculty & Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.
Course Director and Interviewee
Peter C. Taylor, MA, PhD, FRCP
Norman Collisson Professor of Musculoskeletal Sciences
Kennedy Institute of Rheumatology
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences
University of Oxford
Botnar Research Centre
Headington, Oxford, United Kingdom
Peter C. Taylor, MA, PhD, FRCP, has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Bristol-Myers Squibb; Hoffmann-La Roche Ltd; Merck & Co., Inc.; Nycomed (Takeda Pharmaceuticals International); Pfizer Inc and UCB S.A.
Grant/Research Support from AstraZeneca and Celgene Corporation.
Speakers Bureau participant with Pfizer Inc and UCB S.A.
Jonathan Kay, MD
Professor of Medicine
University of Massachusetts Medical School
Director of Clinical Research, Division of Rheumatology
UMass Memorial Medical Center
Jonathan Kay, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Bristol-Myers Squibb; Celgene Corporation; Crescendo Bioscience, Inc.; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Molecular Partners; Pfizer Inc; Savient Pharmaceuticals, Inc.; and UCB S.A.
Grant/Research Support from Abbott Laboratories; Ardea Biosciences, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Fidia Farmaceutici s.p.a.; and sanofi-aventis.
Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education
Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.
Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.
Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.
Sponsorship, Credit & Support
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Penn State College of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5074-12-T.
This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from
Disclosure of Unlabeled Use
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.